Replies to post #20 on Annovis Bio Inc (ANVS)

[McMagyar]

Maxim as just raised Target Valuation of Cassava to almost $3 Billion!

granted Cassava does have AD test potential and is further along Clinical Trial Trail than Annovis..BUT..

A similar Target Valuation for Annovis of around $3 Billion ,
assuming a 25% increase in outstanding shares for Capital Raise,,
10 Million shares (after potential capital raise) $3 Billion MC

Equals $300 PS..that is MY 12 month Target Range..

Caveat Emptor.. I do not disclose buying or selling or positions..so as
always..DO YOUR OWN DUE DILLIGENCE, adn NEVER risk more than you may afford to lose..